 
September 7, 2010
New Trials of HIV-Fighting Vaginal Gel Lack Funding
A promising HIV-fighting vaginal gel may be shelved due to lack of funding, The New York Times reports. In July, scientists announced that women who used a vaginal gel with the antiretroviral drug tenofovir before and after sex were 39 percent less likely overall to contract HIV. To confirm those results, researchers have called for two more trials in Southern Africa costing about $100 million. To date, only about $58 million has been collected. Most of the 22 million people with HIV in sub-Saharan Africa are women.
To read the Times article, click here.
Search: trials, HIV, vaginal gel, funding, AIDS, Africa, New York Times, antiretroviral, tenofovir
Scroll down to comment on this story.
Show comments (1 total)
[Go to top]
|
